{"schema_version":"secwatch.filing_event.v1","accession":"0000885725-23-000041","form_type":"8-K","ticker":"BSX","cik":"0000885725","company_name":"BOSTON SCIENTIFIC CORP","filed_at":"2023-07-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.878688+00:00","generated_at":"2026-06-13T01:49:37.184469+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Boston Scientific Q2 beats: $3.599B revenue (+11% reported), adj. EPS $0.53 vs guidance $0.48-$0.50","bullets":["Revenue $3.599B, +11% reported, +11.6% organic; beat guidance of 6.5-8.5% reported.","GAAP EPS $0.18 (GAAP net income $261M); adjusted EPS $0.53 vs guidance $0.48-$0.50.","Cardiovascular segment grew 12.2% reported; MedSurg grew 9.0% reported.","Full-year 2023 guidance raised: reported revenue growth ~10.5-11.5%, adj. EPS $1.96-$2.00.","Q3 guidance: reported revenue growth 8.5-10.5%, adj. EPS $0.46-$0.48."],"urls":{"canonical":"https://secwatch.observer/filing/0000885725-23-000041","json":"https://secwatch.observer/filing/0000885725-23-000041.json","markdown":"https://secwatch.observer/filing/0000885725-23-000041.md","text":"https://secwatch.observer/filing/0000885725-23-000041.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/885725/000088572523000041/0000885725-23-000041-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/885725/000088572523000041/bsx-20230727.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T01:49:37.184469+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bd90918969e9011fd6b57caed7a97be27bcfe6e9","claim":"BOSTON SCIENTIFIC CORP reported the second quarter ended June 30, 2023 results: revenue $3.599 billion, net income $261 million, EPS $0.18 per share (EPS).","evidence_excerpt":"Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.599 billion during the second quarter of 2023, growing 11.0 percent on a reported basis, 12.0 percent on an operational 1 basis and 11.6 percent on an organic 2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $261 million or $0.18 per share (EPS), compared to $246 million or $0.17 per share a year ago, and achieved adjusted 3 EPS of $0.53 for the period, compared to $0.44 a year ago.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/885725/000088572523000041/0000885725-23-000041-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Revenue","value":"$3.599 billion"},{"label":"Net income","value":"$261 million"},{"label":"EPS","value":"$0.18 per share (EPS)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}